Medindia

X

FDA Offers Full Approval for Amgen’s Blood Cancer Drug ‘Krypolis’

by Reshma Anand on  January 23, 2016 at 2:34 PM Corporate News   - G J E 4
The US food and Drug Administration has announced that it has approved Amgen's supplemental new drug application for Kyprolis in combination with dexamethasone and Revlimid (lenalidomide) for the treatment of refractory multiple myeloma.
FDA Offers Full Approval for Amgen’s Blood Cancer Drug ‘Krypolis’
FDA Offers Full Approval for Amgen’s Blood Cancer Drug ‘Krypolis’
Advertisement

Krypolis can now be used for treating patients with relapse or refractory multiple myeloma who have received one to three treatment before.

‘FDA approves Amgen’s drug, Krypolis in combination with Revlimid and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.’
Advertisement
The drug was approved as a single agent by the FDA in 2012 and now it has expanded it into full approval.

Amgen said, "The agency approved Kyprolis in combination with dexamethasone or with the drug lenalidomide plus dexamethasone for relapsed or refractory patients. It approved the drug as a single agent for patients with relapsed or refractory disease who have received one or more treatments."

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All